TOP1 and neoplasm: Although TOP1 inhibitors effectively induce cancer cell death, their potential applicability is limited by: (i) their rapid elimination before achieving therapeutic concentrations in the tumor; and (ii) dose limitations dictated by the inhibition of TOP1 in normal cells, which need topoisomerase activity for cell survival.